NEW YORK, March 16, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Growth Factors ( Blood And Tissue ) Industry
http://www.reportlinker.com/p0397766/Global-Growth-Factors--Blood-And-Tissue--Industry.html
This report analyzes the worldwide markets for Growth Factors (Blood And Tissue) in US$ Million by the following growth factor types: Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins), and Tissue Growth Factors. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report profiles 88 companies including many key and niche players such as Alseres Pharmaceuticals, Inc., Amgen, Inc., Bayer HealthCare Pharmaceuticals Inc., BioMimetic Therapeutics, Inc., Biopharm GmbH, Bolder Biotechnology, Inc., Ceregene Inc., FibroGen Inc., FzioMed Inc., Novo Nordisk A/S, Reliance GeneMedix Plc, Insmed Inc., Johnson & Johnson, Janssen-Ortho, Inc., Lonza Group, Maxygen, Inc., Merck Serono International S.A., NsGene A/S, PeproTech, Inc., Rentschler Biotechnologie GmbH, F. Hoffmann-La Roche Ltd., Chugai Pharmaceutical Co. Ltd., Genentech, Inc., Shantha Biotechnics, Scil Proteins GmbH, and Wockhardt Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
GROWTH FACTORS (BLOOD AND TISSUE) MCP-1217
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 2
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
Blood Growth Factors 4
Erythropoietins 4
Colony Stimulating Factors 4
Interferons 4
Interleukins 4
Tissue Growth Factors 4
2. INTRODUCTION 6
Growth Factors: A Preface 6
Current and Future Analysis 6
Analysis By Region 6
US - The Single Largest Market 6
Growth Factors Market in Europe 6
Market for Growth Factors in Rest of World 6
Table 1: World Market for Growth Factors (2007-2015):
Geographic Regions Ranked by CAGR - US, Japan, Rest of
World, and Europe (includes corresponding Graph/Chart) 7
Analysis by Growth Factor Type 7
Growth Factors: Their Role and Related Applications 8
Growth Factors: Adding a New Dimension 8
Growth Factors: Classification Based on Activity 8
Recent Trends & Developments 8
Recombinant Human Erythropoietin: Gradually Gaining Dominance 9
Leading EPO Drugs Worldwide 9
Market Comparison of Erythropoietin-Based Drugs in America
and European Union 9
Patent Expiries of Major Biopharmaceutical Drugs: 2001-2007 10
Patent Expiries of Select Biopharmaceuticals in Europe
and United States: 2010 and Beyond 10
3. MARKET DYNAMICS 11
Major Companies Impacted by Patent Expiries 11
Patent Expiries Fuel Competition and Sales 11
Side Effects - Still a Concern 11
CDER- A Regulatory Review Authority for Growth Factors 11
Innovative Delivery System Shows Potential for Accelerating
Use of Growth Factors 12
Cytokines- Vital Growth Propellers for the Future of New Drugs 12
Brain Derived Neurotrophic Factor (BDNF) Finds Increased
Application 12
Age-Related Diseases - Their Influence on Effective Therapies 12
Mimetic Growth Factors - Exhibiting Promising Potential 13
India - At the Center Stage 13
4. INDUSTRY ISSUES 14
Development of Cost Effective Methods - Need of the Hour 14
Influence of Neurotrophic Factors on Brain Cell Development 14
Combination of Interferons and Ribavirin Develops More Anemia
Cases 14
5. GROWTH FACTORS - AN OVERVIEW 15
Blood Growth Factors 15
Erythropoietins 15
Types of Erythropoietins 16
Epoetin 16
Darbepoetin 16
Aranesp® 16
Aranesp Vs. Other EPOs 16
Recombinant Human EPO (rHuEPO) 16
Table 2: World Market for Erythropoietins (2007-2015):
Geographic Regions Ranked by CAGR -Rest of World, Japan, US
and Europe (includes corresponding Graph/Chart) 17
Colony Stimulating Factors 17
Granulocyte-Colony Stimulating Factor 17
Granulocyte Macrophage-Colony Stimulating Factor 18
Other Colony Stimulating Factors 18
Macrophage Colony Stimulating Factor (M-CSF) 18
Key Functions of M-CSF 18
Side-Effects of Colony-Stimulating Factors 18
Table 3: World Market for Colony Stimulating Factors
(2007-2015): Geographic Regions Ranked by CAGR - Europe,
US, Japan and Rest of World (includes corresponding
Graph/Chart) 19
Interferons 19
Types of Interferons 19
Interferon-gamma 20
1a and 1b: Two Key Biochemical Forms of Interferon-ß 20
PEG-Intron 20
Types of Interferons 20
Table 4: World Market for Interferons as Blood Growth
Factors (2007-2015): Geographic Regions Ranked by CAGR -
US, Europe, Japan, and Rest of World (includes
corresponding Graph/Chart) 21
Interleukins 21
Types of Interleukins 21
Table 5: World Market for Interleukins as Blood Growth
Factors (2007-2015): Geographic Regions Ranked by CAGR -
Europe, Rest of World, Japan and US (includes corresponding
Graph/Chart) 22
Tissue Growth Factors 23
Wound Healing Growth Factors 23
Neurotrophic Growth Factors 23
Nerve Growth Factor 23
Vascular Endothelial Growth Factor (VEGF) 23
Fibroblast Growth Factor (FGF) 24
Insulin-Like Growth Factor-I (IGF-I) 24
Insulin-Like Growth Factor-II (IGF-II) 24
Tissue Growth Factors: Classification Based on Key Source
and Principal Activity 24
Platelet - Derived Growth Factors in Wound Healing 24
Thrombopoietin (TPO) 25
Table 6: World Market for Tissue Growth Factors
(2007-2015): Geographic Regions Ranked by CAGR - US,
Europe, Japan, and Rest of World (includes corresponding
Graph/Chart) 25
Growth Factors: Their Mode of Action in Tissue Repair 25
Angiogenesis: Their Role in Wound Healing 26
Angiogenesis As an Alternative for Cardiac Stents 26
Applications of Growth Factors 26
Growth Factors: Suppliers and Applications 27
Growth Factors: Site/Course of Action and Applications 27
6. RESEARCH AND DEVELOPMENT HIGHLIGHTS A RECENT PAST PERSPECTIVE 28
Maxygen Updates on Factor VII Program 28
Evaluation of Extended Dosing Schedule of PROCRIT® 28
PROCRIT® - A Better Option 28
Nerve Growth Factor Shows Promising Potential Against Diabetes 28
Cytokines and GM-CSF Found to be Closely Interlinked 29
GM-CSF Enhances Rate of Survival in Neonates 29
rG-CSF Well Tolerated in Pneumonia and Severe Sepsis Patients 30
rG-CSF- Their Influence on Preterm Infants with Sepsis 30
Serum Macrophage Colony Stimulating Growth Factors Associated
with Thrombocyte and Monocyte 30
Src Pathway Inactivation in Kit Impairs Blood Cell Growth and
Proliferation 30
Cole Eye Institute Offers TIMP-3 Mechanism for Preventing
Abnormal Growth of Blood Vessels 31
Effect of Brain Derived Neurotrophic Factor on Retinal Cells 31
Orcel™ Exhibits High Growth Factor for Wound Healing and
Cardiovascular Applications 32
Drug Combination of Macrophage Colony Stimulating Factor Shows
Successful Tolerance Levels 32
Neotrofin™ Triggers Neurotrophic Factors 32
G-CSF Shows Capability for Promoting Neutrophil Production 33
Insulin-like Growth Factor-1 (IGF) Gene Transfer Accelerates
Wound Healing Process 33
Hepatocyte Growth Factors - Exhibiting Dual Role 34
Cortex Pharmaceuticals Ampakines® Promotes Expression of
Neurotrophin 34
Granulocyte Colony Stimulating Factor Finds Application in
Treating Neonates 34
Cerebrolysin Promotes Cognition 34
7. BREAKTHROUGHS - A RECENT PAST REVIEW 35
Novel Set of Human Cytokines Unveiled 35
IGFBP-3 and its Potential to Ward Off Gastric Cancer 35
Bone Morphogenic Proteins Show Potential for Musculoskeletal
Regeneration 35
Growth Factors - Their Role in Preventing Heart Stroke 35
Growth Factor Proteins Show Promising Results for Treating Cancer 35
Neurotrophic Growth Factor - Primarily Responsible for Loss of
Vision 36
Redox-Active Grape Seed Exhibits Favorable Properties for
Dermal Wound Healing 36
Role of Brain-Derived Neurotrophic Factor on Memory 36
Nerve Growth Factor Found to Enhance Barium Current and
Insulin Secretion 36
Lipid Peroxidation May be Associated with Wound Healing 37
Genentech Inc Unveils Molecule for Stimulating Growth of Blood
Vessels 37
Connective Tissue Growth Factor Found to Promote Lung Fibroblast 37
Influence of Insulin-Like Growth Factor on Growth 38
Regeneron Discovers Angiopoietins Targeted at Blood Vessel
Growth and Repair 38
Environment and Insulin-Like Growth Factors Stimulate Risk of
Cancer 38
Cocktail of Neurotrophic Factors Promotes Regeneration of Torn
Nerves 38
Growth Factors Administration to Stimulate Tissue Repair 39
Cytokine - Their Role in Combating Hepatitis C Virus 39
Axokine® Yields Favorable Results Against Obesity 39
Cell Genesys Unveils GDNF Gene Therapy Targeted Against
Parkinson's Disease 39
8. PRODUCT LAUNCHES 40
Sandoz Unveils Zarzio 40
Wockhardt Launches Three Biotechnology Products 40
Extavia® Receives Approval from European Commission 40
Amgen Bags EC Approval on Use of Aranesp(R) in Paediatric
Patients 41
Hospira Receives EC Approval on Retacrit 41
Tercica Receives FDA Approval For Increlex 41
Ventria Bioscience Introduces Lacromin 41
Dragon Pharmaceuticals Bags Market Approval from Chinese SDA 41
DPI Receives Approvals for Erythropoietin in Three New Markets 42
Wockhardt Introduces Wepox Recombinant Erythropoietin Drug 42
Shanta Biotechnics Unveils Shanferon 42
SkinMedica Unveils TNS Recovery Complex™ Gel 42
CellGenix Unveils Cytokines for Cell Applications 42
Cel-Sci Corporation Develops Multikine 43 Wockhardt Limited
Unveils EPOX™ 43
9. RECENT INDUSTRY ACTIVITY 44
Soluble Systems Collaborates with LifeNet Health's Subsidiary
to Introduce TheraSkin™ 44
GlaxoSmithKline and JCR Pharmaceuticals Enters into Partnership 44
Kaken Pharmaceutical Enters into Licensing Agreement with
Olympus Corporation 44
Biovitrum and Amgen Sign Agreement 45
Merck Establishes Production Unit 45
Eli Lilly and Company Acquires ImClone Systems 45
GeneMedix Changes Name to Reliance GeneMedix 46
FDA Approves Label Expansion for VIDAZA 46
Pfizer Inks Exclusive Global Licensing Agreement with Scil
Technology 46
ZGEN Initiates Ph II Trial of Interleukin 21 47
FzioMed Bags Health Canada Approval on Oxiplex® 47
NsGene A/S Implants Encapsulated Cell in Patients 47
10. INDUSTRY ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER 48
Reliance Life Sciences Takes Over Genemedix 48
Fraunhofer Institute Introduces First Interferon Beta 1a to
Treat Multiple Sclerosis 48
Shanghai Wanxing Inks Export Deal for Recombinant Human
Interferon 48
Hemispherx Enters into Distribution Agreement with Armada 49
Bayer Establishes US Pharmaceuticals Subsidiary 49
Merck Inks Agreement with Bristol-Myers Squibb and ImClone 49
CoGenesys Signs Global Licensing Agreement with Vegenics 49
InterMune Inks New Supply Deal with Boehringer Ingelheim 50
Boston Life Sciences Adopts New Name of Alseres Pharmaceuticals 50
Cambrex Divests Bioproducts and Biopharma Subsidiaries 50
Dragon Divests EPO Business 51
Caregene and Genzyme Forms Partnership to Develop Cere-120 51
NsGene to Undertake Phase Ib Clinical Trial of NsG0202 51
Roche Receives European approval for NeoRecormon 51
Bolder Receives Two U.S. Patents for Hematopoietic Factors 52
RLS to Initiate Clinical Trials of Erythropoietin 52
InterMune Drops Phase III trial of Interferon 52
Chugai to Conduct Additional Trial on Epogin® 52
Merck KGaA Acquires Serono Labs 52
CytoPharm Acquires Low-Dose Interferon License from Amarillo
Biosciences 53
Hospira Signs Agreements with STADA and BIOCEUTICALS for
Erythropoietin 53
Biocon Bags GEAC Approval to Conduct Clinical Trial of
Granulocyte Colony Stimulating Factor 53
SII to Conduct Clinical Trials of Rdna Products 53
Claris to Construct Production Facility for EOP 54
Mayne and Pliva to End Collaboration on Erythropoietin
Development 54
GeneMedix Collaborates with CJ Corp. 54
FzioMed and USC Enter into Licensing Agreement for Oligopeptides 54
AnGes MG Enters Into An Agreement with Vical 55
Corautus and BIA Sign Agreement for VEGF-2 plasmid DNA 55
Dragon Pharmaceuticals Acquires Oriental Wave 55
Insmed Enters into Exclusive Agreement with UCSF for IGF-1 Series 55
Amrad and Ludwig Institute Jointly Focus on the Development of
VEGF-B 55
GeneMedix Restructures Business 56
pSivida Limited Collaborates with Ian Wark Research Institute 56
Amgen Acquires Tularik 56
BMPI Signs up Luitpold Pharmaceuticals for FDA Approved GEM 21S™ 56
Chugai and Roche Expand Drug Research Synergies 56
Dragon Pharmaceuticals to Construct New Production Facility 57
FibroGen Signs Contract with Yamanouchi for Licensing EPO
Small Molecule 57
Insmed and Tzamal Pharma Sign Agreement for Promoting SomatoKine 57
Maxygen and Rentschler Enter into a Contract for G-CSF 57
Maxygen Signs Agreement with Biovitrum for Manufacturing Beta
Interferon 57
Dragon Pharmaceuticals Signs Agreement with Zhongkai 58
Dragon Pharmaceuticals Enters into Definitive Agreement with
Oriental Wave 58
Zymogenetics Bags US FDA Clearance 58
Ceregene Bags Patent 58
AME Enters into Third Collaboration with Eli Lilly and Company 58
ViaCell Enters into Licensing Agreement and Collaboration with
Amgen 59
Ceregene Enters into Licensing Agreement with Genentech 59
BIOPHARM GmbH Enters into Licensing Contract with DePuy 59
Maxygen Enters into a Deal with Roche Holding 59
GeneMedix Signs Agreement with SkyePharma 60
Neurotech Enters into Licensing Agreement with Amgen 60
Ceregene Enters into a Licensing Agreement with Washington
University 60
NeoTherapeutics Receives US Patent for Stimulating Neuritogenesis 60
BioSET Bags Global Exclusive License for Novel Growth Factor
Technology 60
ViaCell Acquires Cerebrotec 60
Fibrogen Collaborates with Sankyo 61
Prescient NeuroPharma Collaborates with SRIB 61
Dragon Pharmaceuticals Signs Agreement with Renapharm AB and
Transworld 61
Baxter Bags Exclusive Worldwide Rights for Epoetin Omega 61
Ortec International Bags FDA PMA for OrCel 61
GeneMedix Bags Chinese SDA Approval 62
NsGene Collaborates with ARIAD Pharmaceuticals 62
Regeneron Enters into Agreement with Emisphere Technologies 62
NsGene A/S Signs Agreement with Biogen Inc 62
NTB Enters into BioInformatics Outsourcing Agreement with HSC 63
11. FOCUS ON SELECT GLOBAL PLAYERS 64
Alseres Pharmaceuticals, Inc. (USA) 64
Amgen, Inc. (USA) 64
Bayer HealthCare Pharmaceuticals Inc. (USA) 64
BioMimetic Therapeutics, Inc. (USA) 65
Biopharm GmbH (Germany) 65
Bolder Biotechnology, Inc. (USA) 65
Ceregene, Inc. (USA) 65
FibroGen, Inc. (USA) 66
FzioMed, Inc. (USA) 66
Novo Nordisk A/S (Denmark) 66
Reliance GeneMedix Plc. (UK) 66
Insmed, Inc. (USA) 67
Johnson & Johnson (USA) 67
Janssen-Ortho, Inc. (Canada) 68
Lonza Group (Switzerland) 68
Maxygen, Inc. (USA) 68
Merck Serono International S.A. (Switzerland) 69
NsGene A/S (Denmark) 69
PeproTech, Inc. (USA) 69
Rentschler Biotechnologie GmbH (Germany) 69
F. Hoffmann-La Roche Ltd (Switzerland) 70
Chugai Pharmaceutical Co. Ltd. (Japan) 70
Genentech, Inc. (USA) 70
Shantha Biotechnics (India) 71
Scil Proteins GmbH (Germany) 71
Wockhardt Ltd. (India) 71
12. GLOBAL MARKET PERSPECTIVE 72
Table 7: World Recent Past, Current & Future Analysis for
Growth Factors (Blood and Tissue) by Geographic Region - US,
Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2007
through 2015 (includes corresponding Graph/Chart) 72
Table 8: World Historic Review for Growth Factors (Blood and
Tissue) by Geographic Region - US, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 73
Table 9: World 11-Year Perspective for Growth Factors (Blood
and Tissue) by Geographic Region - Percentage Breakdown of
Value Sales for US, Japan, Europe, and Rest of World Markets
for 2005, 2010 & 2015 (includes corresponding Graph/Chart) 74
Table 10: World Recent Past, Current & Future Analysis for
Blood Growth Factors by Geographic Region - US, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Sales in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 75
Table 11: World Historic Review for Blood Growth Factors by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 76
Table 12: World 11-Year Perspective for Blood Growth Factors
by Geographic Region - Percentage Breakdown of Value Sales for
US, Japan, Europe, and Rest of World Markets for 2005, 2010 &
2015 (includes corresponding Graph/Chart) 77
Table 13: World Recent Past, Current & Future Analysis for
Blood Growth Factors by Type - Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2007 through 2015 (includes corresponding Graph/Chart) 78
Table 14: World Historic Review for Blood Growth Factors by
Type - Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 79
Table 15: World 11-Year Perspective for Blood Growth Factors
by Type - Percentage Breakdown of Value Sales for
Erythropoietins, Colony Stimulating Factors, Interferons and
Interleukins Markets for 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 80
Table 16: World Recent Past, Current & Future Analysis for
Erythropoietins by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 81
Table 17: World Historic Review for Erythropoietins by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 82
Table 18: World 11-Year Perspective for Erythropoietins by
Geographic Region - Percentage Breakdown of Value Sales for
US, Japan, Europe, and Rest of World Markets for 2005, 2010 &
2015 (includes corresponding Graph/Chart) 83
Table 19: World Recent Past, Current & Future Analysis for
Colony Stimulating Factors by Geographic Region - US, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) 84
Table 20: World Historic Review for Colony Stimulating Factors
by Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 85
Table 21: World 11-Year Perspective for Colony Stimulating
Factors by Geographic Region - Percentage Breakdown of Value
Sales for US, Japan, Europe, and Rest of World Markets for
2005, 2010 & 2015 (includes corresponding Graph/Chart) 86
Table 22: World Recent Past, Current & Future Analysis for
Interferons as Blood Growth Factors by Geographic Region - US,
Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2007
through 2015 (includes corresponding Graph/Chart) 87
Table 23: World Historic Review for Interferons as Blood
Growth Factors by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 88
Table 24: World 11-Year Perspective for Interferons as Blood
Growth Factors by Geographic Region - Percentage Breakdown of
Value Sales for US, Japan, Europe, and Rest of World Markets
for 2005, 2010 & 2015 (includes corresponding Graph/Chart) 89
Table 25: World Recent Past, Current & Future Analysis for
Interleukins as Blood Growth Factors by Geographic Region -
US, Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2007
through 2015 (includes corresponding Graph/Chart) 90
Table 26: World Historic Review for Interleukins as Blood
Growth Factors by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 91
Table 27: World 11-Year Perspective for Interleukins as Blood
Growth Factors by Geographic Region - Percentage Breakdown of
Value Sales for US, Japan, Europe, and Rest of World Markets
for 2005, 2010 & 2015 (includes corresponding Graph/Chart) 92
Table 28: World Recent Past, Current & Future Analysis for
Tissue Growth Factors by Geographic Region - US, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) 93
Table 29: World Historic Review for Tissue Growth Factors by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 94
Table 30: World 11-Year Perspective for Tissue Growth Factors
by Geographic Region - Percentage Breakdown of Value Sales for
US, Japan, Europe, and Rest of World Markets for 2005, 2010 &
2015 (includes corresponding Graph/Chart) 95
13. THE UNITED STATES 96
A. Market Analysis 96
Current and Future Analysis 96
Leading EPO Drugs in the US 96
B. Market Analytics 97
Table 31: US Recent Past, Current & Future Analysis for
Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2007 through 2015 (includes corresponding Graph/Chart) 97
Table 32: US Historic Review for Growth Factors by Type -
Blood Growth Factors (Erythropoietins, Colony Stimulating
Factors, Interferons and Interleukins) and Tissue Growth
Factors Markets Independently Analyzed with Annual Sales in
US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 98
Table 33: US 11-Year Perspective for Growth Factors by Type -
Percentage Breakdown of Value Sales for Blood Growth
Factors (Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins) and Tissue Growth Factors
Markets for 2005, 2010 & 2015 (includes corresponding
Graph/Chart) 99
14. JAPAN 100
A. Market Analysis 100
Current and Future Analysis 100
Erythropoietin Market 100
Leading EPO Drugs in Japan 100
Market Scenario for Biotech Products 100
Biotech Market Backed by Public Assistance 100
B. Market Analytics 101
Table 34: Japanese Recent Past, Current & Future Analysis
for Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2007 through 2015 (includes corresponding Graph/Chart) 101
Table 35: Japanese Historic Review for Growth Factors by
Type - Blood Growth Factors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and
Tissue Growth Factors Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 102
Table 36: Japanese 11-Year Perspective for Growth Factors by
Type - Percentage Breakdown of Value Sales for Blood Growth
Factors (Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins) and Tissue Growth Factors
Markets for 2005, 2010 & 2015 (includes corresponding
Graph/Chart) 103
15. EUROPE 104
A. Market Analysis 104
Current and Future Analysis 104
Erythropoietin Market Scenario in the Recent Past 104
Leading EPO Drugs in Europe 104
B. Market Analytics 105
Table 37: European Recent Past, Current & Future Analysis
for Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2007 through 2015 (includes corresponding Graph/Chart) 105
Table 38: European Historic Review for Growth Factors by
Type - Blood Growth Factors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and
Tissue Growth Factors Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 106
Table 39: European 11-Year Perspective for Growth Factors by
Type - Percentage Breakdown of Value Sales for Blood Growth
Factors (Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins) and Tissue Growth Factors
Markets for 2005, 2010 & 2015 (includes corresponding
Graph/Chart) 107
16. REST OF WORLD 108
A. Market Analysis 108
Current and Future Analysis 108
An Overview of Indian Market 108
Erythropoietin 108
G-CSF Market 109
Interferon 109
B. Market Analytics 110
Table 40: Rest of World Recent Past, Current & Future
Analysis for Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2007 through 2015 (includes corresponding Graph/Chart) 110
Table 41: Rest of World Historic Review for Growth Factors
by Type - Blood Growth Factors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and
Tissue Growth Factors Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 111
Table 42: Rest of World 11-Year Perspective for Growth
Factors by Type - Percentage Breakdown of Value Sales for
Blood Growth Factors (Erythropoietins, Colony Stimulating
Factors, Interferons and Interleukins) and Tissue Growth
Factors Markets for 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 112
COMPETITIVE LANDSCAPE
Total Companies Profiled: 88 (including Divisions/Subsidiaries - 100)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 54
Canada 3
Japan 5
Europe 21
Germany 11
The United Kingdom 2
Rest of Europe 8
Asia-Pacific (Excluding Japan) 14
Middle-East 3
------------------------------------------
To order this report:
: Global Growth Factors ( Blood And Tissue ) Industry
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT: |
|
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article